David W. Kimberlin, MD
University of Alabama-Birmingham (Birmingham, AL)
Dr. Kimberlin is Professor of Pediatrics at the University of Alabama at Birmingham, where he holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases and is Co-Director of the Division of Pediatric Infectious Diseases. He leads the pediatric studies conducted by the Collaborative Antiviral Study Group, and with the CASG, has defined the standard of care for the antiviral treatment of neonatal herpes simplex virus infections and congenital cytomegalovirus disease. He is a past President of the Pediatric Infectious Diseases Society, an editor of the American Academy of Pediatrics Nelson’s Pediatric Antimicrobial Therapy textbook, and also is the Editor of the American Academy of Pediatrics Red Book: Report of the Committee on Infectious Diseases.
Peter G. Pappas, MD
University of Alabama-Birmingham (Birmingham, AL)
Dr. Pappas is a Professor of Medicine in the Division of Infectious Diseases and Tinsley Harrison Clinical Scholar in the Department of Medicine at the University of Alabama in Birmingham. He is currently the Principal Investigator of the Mycoses Study Group Education and Research Consortium (MSG), a recently reorganized clinical trials group and educational organization. He was the Principal Investigator of a national network of transplant centers, TRANSNET, in conjunction with the CDC. TRANSNET provided important epidemiologic and treatment information concerning transplant recipients who develop proven and probable invasive fungal infections. Finally, he is co-Principal Investigator of the Organ Transplant Infection Detection and Prevention Program (OTIPP), a collaborative multicenter group funded through the CDC. His research interests include transplant associated infections including the invasive mycoses. In addition, he has an interest in the diagnosis, epidemiology and new therapeutic approaches for invasive candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis, and histoplasmosis. Much of this work is accomplished through research networks such as the MSG and TRANSNET.
David Denning, FRCP, FRCPath, DCH, FMedSci
The University of Manchester (Manchester, UK)
Dr. Denning is a Professor of Medical Mycology at the University of Manchester. He directs the National Aspergillosis Centre (Manchester), which is the referral centre in the UK for all patients with chronic pulmonary aspergillosis. His group undertakes basic research (genomics, pathogenesis and mechanisms of antifungal drug resistance), applied laboratory work (molecular and serological diagnostics), and clinical studies (description of the natural history of fungal infection, human genetics of aspergillosis and therapy studies). His current foci of interest are chronic and allergic pulmonary fungal disease, the global burden of fungal infection and azole resistance in Aspergillus. He is the Founder of two University spinout biotechnology companies – F2G Ltd. (antifungal drug discovery and development) and Myconostica Ltd. (molecular diagnostic tests for fungi), now sold to Lab21. He is the managing editor of The Aspergillus and Aspergillosis Website since 1998 with over one million pages read per month. He has chaired the Scientific Committees of several international fungal infection meetings, and co-chairs the alternate year Advances Against Aspergillosis scientific meetings. He now also leads Leading International Fungal Education (LIFE), which is focused on improving patient outcomes through advocacy and education.
Tom M. Chiller, MD, MPHTM
Centers for Disease Control & Prevention (Atlanta, GA)
Dr. Chiller is the Associate Director for Epidemiologic Science in the Division of Foodborne, Waterborne, and Environmental Diseases at the National Center for Emerging and Infectious Zoonotic Diseases (NCEZID). He also serves as the Deputy Chief of the Mycotic Diseases Branch. He serves as the CDC’s main interface regarding fungal infection outbreaks as well as surveillance.
The IPFN has two advisory boards composed of international experts in the treatment and diagnosis of invasive fungal infections.
Therapeutic Study Advisory Board
Diagnostic Study Advisory Board
Peter Donnelly, PhD, FRCPath
Radboud University Nijmegen Medical Centre & Nijmegen Institute for Infection (Nijmegen, The Netherlands)
Dr. Donnelly is in the Department of Haematology at Radboud University Medical Centre in Nijmegen. He is Chair of the Infectious Disease Group of the European Organization for Research and Treatment of Cancer (EORTC). He serves as Chair of the European Aspergillus PCR Initiative (EAPCRI), is a member of the European Group for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and was General Secretary to ISHAM. Some of his research interests are the epidemiology, diagnosis and management of invasive fungal diseases and infectious complications of neutropenic patients.
Barbara Alexander, MD
Duke University Medical Center (Durham, NC)
Dr. Alexander is a Professor of Medicine and Professor of Pathology at Duke University. She is the Director of the Transplant Infectious Diseases Service at Duke University Medical Center as well as Head of the Clinical Mycology Laboratory. She is the Driector of the Duke Transplant Infectious Disease NIH-finded training grant. She was on the Steering Committee of the NIAID-funded Aspergillus Diagnostics Consortium (AsTeC) and an expert in biomarkers for diagnosis and antifungal agents for treating invasive fungal infections.
Luis Ostrosky-Zeichner, MD
University of Texas Health Science Center at Houston (Houston, TX)
Dr. Ostrosky-Zeichner is Professor of Medicine and Epidemiology, and the Director of the Laboratory of Mycology Research, at the Division of Infectious Diseases of the University of Texas Medical School at Houston. He also serves as the Associate Fellowship Program Director and Medical Director for epidemiology for Memorial Hermann Texas Medical Center. He is an editor for Journal of Antimicrobial Chemotherapy and an editorial board member of Antimicrobial Agents and Chemotherapy, Critical Care Medicine, and Journal of Clinical Microbiology. He is an international expert in the diagnosis and treatment of invasive candidiasis.
International Pediatric Fungal Network, Box 3499, Duke University Medical Center, Durham, NC 27710. USA. Tel: 919-668-4847 Email: PFNContracts@duke.edu
Daniel Benjamin Jr., MD, PhD, MPH
Dr. Benjamin is Kiser Arena Distinguished Professor of Pediatrics in the Division of Pediatric Infectious Diseases at Duke University Medical Center and the Faculty Director of the Duke Clinical Research Institute. He has been the Protocol Chair and author for eight multi-center trials investigating the pharmacokinetics of antimicrobials in neonates and young children. Dr. Benjamin is the Principal Investigator of the $95M NICHD-funded Pediatric Trials Network and the Chair of the Candidiasis Committee of the NICHD-sponsored Neonatal Research Network.
